Cobant Spółka z Ograniczoną Odpowiedzialnością (KRS 0000489944, NIP 5252576618) is a Polish company, headquartered in Warszawa, Mazowieckie voivodeship. COBANT operates in: Other research and experimental development on natural sciences and engineering (PKD 72.19.Z). Industry: Research and development. The company has been listed in the National Court Register since December 10, 2013. COBANT's most recently reported net revenue was 21.5 M PLN for 2024.
Negative equity
Negative equity in 3 of 4 available reporting years.
No arrears identified in the analyzed sources
No arrears or bankruptcy proceedings identified in the analyzed sources.
Business profile - Cobant
Identity
- Name
- Cobant Spółka z Ograniczoną Odpowiedzialnością
- Legal form
- SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
- Founded
- December 10, 2013
- Registry status as of
- December 4, 2025
- Latest entry
- November 18, 2025
- Founding act
- 15.11.2013 R. NOTARIUSZ PAWEŁ KURCIŃSKI W KANCELARII NOTARIALNEJ W WARSZAWIE PRZY ULICY BONIFRATERSKIEJ 8/99, POD NUMERE…
Articles of association history (2)
- November 15, 2013: 15.11.2013 R. NOTARIUSZ PAWEŁ KURCIŃSKI W KANCELARII NOTARIALNEJ W WARSZAWIE PRZY ULICY BONIFRATERSKIEJ 8/99, POD NUMEREM REP. A NR 4254/2013.
- February 27, 2014: AKTEM NOTARIALNYM Z DNIA 27.02.2014 R., REP. A NR 741/2014, SPORZĄDZONYM PRZEZ ASESORA NOTARIALNEGO RADOSŁAWA WALASIKA ZASTĘPCĘ NOTARIUSZA PAWŁA KURCIŃSKIEGO W KANCELARII NOTARIALNEJ W WARSZAWIE PRZY UL.BONIFRATERSKIEJ 8 LOK.99, ZMIANA: §5, §7 ORAZ §21 UST.3 AKTU ZAŁOŻYCIELSKIEGO
Activities
Main activity
72.19.ZOther research and experimental development on natural sciences and engineering
General codes (divisions and groups)
General codes indicate a PKD division or group without a specific subclass.
Address and contact
- Address
- ALEJA JANA PAWŁA II, 27, 00-867, WARSZAWA, POLSKA
- Voivodeship
- MAZOWIECKIE
- District
- M.ST. WARSZAWA
- Not disclosed in the registry
- Website
- Not disclosed in the registry
- E-delivery address
- AE:PL-56339-91027-RARSU-35
- Coordinates
- 52.2298, 21.0117approx.
Risk and payment profile - Cobant
Credibility rating
30.7 / 100
Poor credibility
Insolvency risk
Moderate
Significant formal threat
Closure risk
31
/ 100
Risk comparison - scale 0 (safe) → 100 (critical)
Organizational stability signals
No instability signals - ownership, management, PKD codes and company name remain relatively stable.
Shareholder changes
4
4/12 yrs
Board changes
4
4/12 yrs
PKD changes
2
2/12 yrs
Name changes
0
0/12 yrs
Data from 12 years of registry activity.
Credibility history
Payment reliability score from 2020–2024
Current: E (31/100)
Trend: improving (+7.4 pts/year)
Bardzo słaba wiarygodność płatnicza – współpraca handlowa wiąże się z wysokim ryzykiem braku zapłaty.
Trade credit limit history
Standard limit from 2020–2024
Current: 1.3 M PLN
Safe: 228.9 K PLN
Operational status - Cobant
Founded
December 10, 2013
12 years in operation
Legal form
SPÓŁKA Z OGRANICZONĄ ODPOWIEDZIALNOŚCIĄ
Registry: RejP
Headquarters
WARSZAWA
MAZOWIECKIE
Primary PKD
72.19.Z
Other research and experimental development on natural sciences and…
Share capital
5.0 K PLN
100 shares total
Shareholders
1
shareholder
Board
1 person
Proxies: 1
Filed years
4 years
2020–2024 · profitable: 0/4
Registry entries
22
latest: November 18, 2025
Risk signals
Revenue
21.5 M PLN
2024
Net profit
-412.7 K PLN
2024
Assets
19.1 M PLN
2024
Equity
-12.4 M PLN
2024
EBITDA
3.3 M PLN
2024
Companies in the same location
Public procurement
Trademarks
Reviews
Rate business credibility - Cobant.
No ratings
Related articles
News
Bioceltix in the final EMA dialogue phase: BCX-CM-J could become Europe's first veterinary cell-therapy drug for dogs
Wrocław-based Bioceltix S.A. (KRS 0000744521) entered Q2 2026 in the final EMA dialogue phase regarding BCX-CM-J - Europe's first veterinary cell-therapy drug from mesenchymal stem cells for dogs with osteoarthritis. Responses to the final EMA questions are due in May 2026; the CVMP recommendation and marketing authorisation are possible in Q3/Q4 2026. Pre-commercial biotech: 2024 closed with a PLN 14.9 m loss on zero revenue; cash of PLN 33.6 m at year-end. Trigon DM maintained a buy rating with a price target of PLN 127.2.
News
Captor Therapeutics: PLN 36 m of cash at 30 September 2025, runway to mid-2026 - clinical data versus the cash clock
Wrocław-based Captor Therapeutics S.A. (KRS 0000756383) - a pre-commercial biotech specialising in TPD (Targeted Protein Degradation) - closed Q3 2025 with PLN 36 m of cash and grants securing financing to mid-2026. CT-01 (hepatocellular carcinoma) entered Phase I - the first patient dosed at Barcelona Clinic Liver Cancer. CT-03 (MCL-1 degrader) nearing clinical entry. Without a new R&D partnership or equity issuance in 2026, the company will need additional financing.
